Print

Active Biotech AB Interim report January - March 2015

2015-04-23

Laquinimod

  • The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016
  • Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25

Tasquinimod

  • Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28)
  • Further development of tasquinimod for the treatment of prostate cancer has been discontinued. The collaboration agreement with Ipsen will accordingly cease.

ISI

  • The project is currently focusing on building up a patent portfolio

Financial summary

MSEK Jan. - Mar. Jan. - Dec.
2015 2014 2014
Net sales 2.9 2.1 10.4
Operating loss -57.4 -59.2 -228.5
Loss for the period -58.0 -60.2 -231.5
Loss per share (SEK) -0.64 -0.80 -3.02
Cash and cash equivalents 270.5 298.5 328.5

For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95



Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
The report is also available at www.activebiotech.com
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

pdfActive Biotech AB Interim report January - March 2015



Back